loading page

Diagnostic and Therapeutic Intervention for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors-associated Cardiotoxicity in Non-small-cell Lung Cancer: A Case Study
  • +5
  • Miwa Kikuchi,
  • Naoki Aizawa,
  • Takahiro Furuya ,
  • Fumito Miyoshi,
  • Keita Shibata ,
  • Naoko Ikeda ,
  • Miki Kushima ,
  • Kaoru Tanno
Miwa Kikuchi
Showa University Koto Toyosu Hospital

Corresponding Author:[email protected]

Author Profile
Naoki Aizawa
Showa University Koto Toyosu Hospital
Author Profile
Takahiro Furuya
Showa University Koto Toyosu Hospital
Author Profile
Fumito Miyoshi
Showa University Koto Toyosu Hospital
Author Profile
Keita Shibata
Showa University Koto Toyosu Hospital
Author Profile
Naoko Ikeda
Showa University Koto Toyosu Hospital
Author Profile
Miki Kushima
Showa University Koto Toyosu Hospital
Author Profile
Kaoru Tanno
Showa University school of Medicine
Author Profile

Abstract

Introduction: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) are the first-line standard of care for patients with advanced non-small-cell lung cancer (NSCLC) harboring EGFR mutations. Rates of serious adverse events are lower with EGFR-TKIs than other drugs. However, some reports have described EGFR-TKI-associated cardiac dysfunction, but the underlying mechanism is currently unclear. Case: A 72-year-old women presented with non-sustained ventricular tachycardia (NSVT) associated with EGFR-TKI. Because the voltage map detected a low voltage area in the right ventricle, ablation was performed. Conclusion: In this patient, NSVT resolved after ablation, and EGFR-TKI could then be readministered at the original dose.